company background image
CNSP

CNS Pharmaceuticals NasdaqCM:CNSP Stock Report

Last Price

US$0.18

Market Cap

US$7.2m

7D

-7.6%

1Y

-87.3%

Updated

03 Oct, 2022

Data

Company Financials +
CNSP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

CNSP Stock Overview

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.

CNS Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CNS Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.18
52 Week HighUS$1.55
52 Week LowUS$0.17
Beta1.33
1 Month Change-27.36%
3 Month Change-31.06%
1 Year Change-87.32%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.06%

Recent News & Updates

Aug 15

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals press release (NASDAQ:CNSP): Q2 Net Loss of $3.6M As of June 30, 2022, the company had cash of approximately $9M and working capital of approximately $10.5M. The company's current expectation is that the cash on hand and the proceeds from the offering during January is sufficient to fund our operations into 2023.

Shareholder Returns

CNSPUS PharmaceuticalsUS Market
7D-7.6%1.2%1.0%
1Y-87.3%4.4%-20.0%

Return vs Industry: CNSP underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: CNSP underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is CNSP's price volatile compared to industry and market?
CNSP volatility
CNSP Average Weekly Movement9.7%
Pharmaceuticals Industry Average Movement11.2%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: CNSP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: CNSP's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20174John Climacohttps://www.cnspharma.com

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals Fundamentals Summary

How do CNS Pharmaceuticals's earnings and revenue compare to its market cap?
CNSP fundamental statistics
Market CapUS$7.21m
Earnings (TTM)-US$12.96m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CNSP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$12.96m
Earnings-US$12.96m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio1.4%

How did CNSP perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CNSP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CNSP?

Other financial metrics that can be useful for relative valuation.

CNSP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does CNSP's PB Ratio compare to its peers?

CNSP PB Ratio vs Peers
The above table shows the PB ratio for CNSP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.7x
BMMJ Body and Mind
0.3xn/aUS$8.5m
NBY NovaBay Pharmaceuticals
0.5x84.1%US$7.2m
PALI Palisade Bio
1.7x7.9%US$7.0m
PRFX PainReform
0.5x-23.3%US$6.9m
CNSP CNS Pharmaceuticals
0.6x-8.6%US$7.2m

Price-To-Book vs Peers: CNSP is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (0.7x).


Price to Earnings Ratio vs Industry

How does CNSP's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: CNSP is good value based on its Price-To-Book Ratio (0.6x) compared to the US Pharmaceuticals industry average (1.7x)


Price to Book Ratio vs Fair Ratio

What is CNSP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CNSP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CNSP's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CNSP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CNSP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CNSP's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is CNS Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-8.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CNSP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CNSP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CNSP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CNSP is forecast to have no revenue next year.

High Growth Revenue: CNSP is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CNSP's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has CNS Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-29.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CNSP is currently unprofitable.

Growing Profit Margin: CNSP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CNSP is unprofitable, and losses have increased over the past 5 years at a rate of 29.8% per year.

Accelerating Growth: Unable to compare CNSP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CNSP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: CNSP has a negative Return on Equity (-112.46%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is CNS Pharmaceuticals's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CNSP's short term assets ($11.4M) exceed its short term liabilities ($923.9K).

Long Term Liabilities: CNSP has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CNSP has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CNSP's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CNSP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CNSP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 54.9% each year


Discover healthy companies

Dividend

What is CNS Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

CNS Pharmaceuticals Dividend Yield vs Market
How does CNS Pharmaceuticals dividend yield compare to the market?
SegmentDividend Yield
Company (CNS Pharmaceuticals)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (CNS Pharmaceuticals)n/a

Notable Dividend: Unable to evaluate CNSP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CNSP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CNSP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CNSP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CNSP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

John Climaco (53 yo)

no data

Tenure

US$845,940

Compensation

Mr. John Michael Climaco, Esq., J.D serves as Chairman of the Board at CNS Pharmaceuticals, Inc. Mr. Climaco has been the Chief Executive Officer of CNS Pharmaceuticals, Inc. since September 2017 and serve...


CEO Compensation Analysis

John Climaco's Compensation vs CNS Pharmaceuticals Earnings
How has John Climaco's remuneration changed compared to CNS Pharmaceuticals's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$846kUS$525k

-US$14m

Sep 30 2021n/an/a

-US$14m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$2mUS$440k

-US$9m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$8m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$1mUS$214k

-US$4m

Sep 30 2019n/an/a

-US$8m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$164kUS$150k

-US$7m

Dec 31 2017US$140kUS$50k

-US$526k

Compensation vs Market: John's total compensation ($USD845.94K) is about average for companies of similar size in the US market ($USD781.86K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CNSP's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: CNSP's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqCM:CNSP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Dec 21BuyUS$4,702Christopher DownsIndividual5,000US$0.94
19 Nov 21BuyUS$5,192Christopher DownsIndividual4,500US$1.15

Ownership Breakdown

What is the ownership structure of CNSP?
Owner TypeNumber of SharesOwnership Percentage
Private Companies200,0000.5%
Institutions1,218,1293.0%
Individual Insiders8,472,78121.2%
General Public30,141,57175.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 45.8%.


Top Shareholders

Top 25 shareholders own 24.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18.32%
Waldemar Priebe
7,333,133$1.3m0%no data
2.35%
John Climaco
940,298$169.3k0%no data
1.07%
The Vanguard Group, Inc.
427,703$77.0k0%no data
0.51%
BNY Mellon Asset Management
203,548$36.6k-13.34%no data
0.5%
Houston Pharmaceuticals, Inc.
200,000$36.0k0%no data
0.46%
Christopher Downs
184,500$33.2k0%no data
0.45%
Virtu Financial LLC, Asset Management Arm
178,184$32.1k59.45%no data
0.32%
Geode Capital Management, LLC
129,016$23.2k0%no data
0.1%
FSM Wealth Advisors, LLC
40,000$7.2k0%no data
0.08%
Northern Trust Global Investments
32,094$5.8k0%no data
0.072%
Tower Research Capital LLC
29,007$5.2k2.05%no data
0.063%
Cambridge Investment Research Advisors, Inc.
25,250$4.5k0%no data
0.052%
Citadel Advisors LLC
20,721$3.7k-62.48%no data
0.05%
Wilcoxson Wealth Management
20,000$3.6k0%no data
0.049%
State Street Global Advisors, Inc.
19,645$3.5k0%no data
0.047%
United Capital Financial Advisers, LLC
18,944$3.4k0%no data
0.04%
HighTower Advisors, LLC
16,000$2.9k18.52%no data
0.033%
Citigroup Inc.,Banking and Securities Investments
13,400$2.4k0%no data
0.03%
Wells Fargo & Company, Securities and Brokerage Investments
12,000$2.2k0%no data
0.028%
Jeffry Keyes
11,100$2.0k0%no data
0.027%
Prime Capital Investment Advisors, LLC
10,727$1.9k0%no data
0.026%
Millennium Management LLC
10,384$1.9k0%no data
0.025%
Alpha Cubed Investments, LLC
10,000$1.8k0%no data
0.0094%
Carl Evans
3,750$675.00%no data
0.0025%
Global Retirement Partners, LLC
1,000$180.00%no data

Company Information

CNS Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: CNS Pharmaceuticals, Inc.
  • Ticker: CNSP
  • Exchange: NasdaqCM
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$7.206m
  • Shares outstanding: 40.03m
  • Website: https://www.cnspharma.com

Number of Employees


Location

  • CNS Pharmaceuticals, Inc.
  • 2100 West Loop South
  • Suite 900
  • Houston
  • Texas
  • 77027
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNSPNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/03 00:00
End of Day Share Price2022/10/03 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.